Identification of Circulating miR-762 as a Novel Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer

Background: MicroRNAs (miRNAs) have been demonstrated to play critical roles in tumorigenesis of non-small cell lung cancer (NSCLC), and circulating miRNAs are a valuable source of biomarkers for the clinical management of NSCLC. The aim of this study was to determine the value of serum miR-762 as a diagnostic and prognostic biomarker for NSCLC. Methods: We examined circulating miR-762 expression in 148 NSCLC patients and 60 healthy individuals using the quantitative real-time polymerase chain reaction (qRT-PCR). The effect of miR-762 downregulation on the proliferative capacity of NSCLC cells were also explored. Results: The serum miR-762 levels were significantly upregulated in NSCLC patients compared to the healthy individuals. Receiver operating characteristics (ROC) curve analysis revealed that circulating miR-762, carcinoembryonic antigen (CEA), CYFRA21-1 and a combination of these 3 biomarkers yield the areas under the curve (AUC) of 0.874, 0.826, 0.41 and 0.969, respectively. Interestingly, circulating miR-762 identified the NSCLC patients at the clinical stage I from healthy controls with an AUC value of 0.920. In addition, serum miR-762 expression was significantly correlated with clinical stage, lymph node metastasis, histological grade and gefitinib-resistance. The survival analysis showed that NSCLC patients in the high serum miR-762 group suffered worse overall survival and relapse-free survival than those in the low serum miR-762 group. The multivariate Cox proportional hazards regression analysis revealed high circulating miR-762 was an independent unfavorable prognostic factor. Downregulation of miR-762 significantly suppressed the proliferative capacity of NSCLC cells in vitro, and bioinformatic analysis of the potential downstream targets of miR-762 identified many important cancer-associated pathways. Conclusions: In conclusion, serum miR-762 might serve as a promising diagnostic and prognostic biomarker for the NSCLC.

Download Full-text

Meta-analysis of segmentectomy versus lobectomy for radiologically pure solid or solid-dominant stage IA non-small cell lung cancer

Journal of Cardiothoracic Surgery ◽

10.1186/s13019-019-0996-6 ◽

2019 ◽

Vol 14 (1) ◽

Cited By ~ 2

Author(s):

Sunyin Rao ◽

Lianhua Ye ◽

Li Min ◽

Guangqiang Zhao ◽

Ya Chen ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Meta Analysis ◽

Clinical Stage ◽

Small Cell ◽

Small Cell Lung ◽

Clinical Stage Ia ◽

Stage Ia ◽

Nsclc Patients

Abstract Objective Whether segmentectomy can be used to treat radiologically determined pure solid or solid-dominant lung cancer remains controversial owing to the invasive pathologic characteristics of these tumors despite their small size. This meta-analysis compared the oncologic outcomes after lobectomy and segmentectomy regarding relapse-free survival (RFS) and overall survival (OS) in patients with radiologically determined pure solid or solid-dominant clinical stage IA non-small cell lung cancer (NSCLC). Methods A literature search was performed in the MEDLINE, EMBASE, and Cochrane Central databases for information from the date of database inception to March 2019. Studies were selected according to predefined eligibility criteria. The hazard ratio (HR) and associated 95% confidence interval (CI) were extracted or calculated as the outcome measure for data combining. Results Seven eligible studies published between 2014 and 2018 enrolling 1428 patients were included in the current meta-analysis. Compared with lobectomy, segmentectomy had a significant benefit on the RFS of radiologically determined pure solid or solid-dominant clinical stage IA NSCLC patients (combined HR: 1.46; 95% CI, 1.05–2.03; P = 0.024) and there were no significant differences on the OS of these patients (HR: 1.52; 95% CI, 0.95–2.43; P = 0.08). Conclusions Segmentectomy leads to lower survival than lobectomy for clinical stage IA NSCLC patients with radiologically determined pure solid or solid-dominant tumors. Moreover, applying lobectomy to clinical stage IA NSCLC patients with radiologically determined pure solid or solid-dominant tumors (≤2 cm) could lead to an even bigger survival advantage. However, there are some limitations in the present study, and more evidence is needed to support the conclusion.

Download Full-text

Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e23035 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e23035-e23035 ◽

Cited By ~ 8

Author(s):

Marco Giallombardo ◽

Jorge Jorge Chacartegui ◽

Pablo Reclusa ◽

Jan P. Van Meerbeeck ◽

Riccardo Alessandro ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Prognostic Biomarker ◽

Small Cell ◽

Small Cell Lung ◽

Exosomal Mirnas ◽

Nsclc Patients ◽

Egfr Mutated

Download Full-text

Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients

Scientific Reports ◽

10.1038/s41598-021-85797-z ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Xiaorong Zhou ◽

Chenchen Li ◽

Zhao Zhang ◽

Daniel Y. Li ◽

Jinwei Du ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Prognostic Biomarker ◽

Tumor Burden ◽

Small Cell ◽

Small Cell Lung ◽

Free Survival ◽

Nsclc Patients ◽

Kinetics Of

AbstractTyrosine kinase inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers including non-small-cell lung cancer (NSCLC). This study aims to evaluate the utility of plasma cell-free DNA (cfDNA) as a prognostic biomarker and efficacy predictor of chemotherapy (CT) with or without these precision therapies in NSCLC patients. Peripheral cfDNA levels in 154 NSCLC patients were quantified before and after the first target cycle of chemotherapy. The correlations of cfDNA with tumor burden, clinical characteristics, progression-free survival (PFS)/disease-free survival (DFS), objective response ratio (ORR), and therapy regimens were analyzed respectively. Baseline cfDNA, but not post-chemotherapeutic cfDNA, positively correlates with tumor burden. Notably, cfDNA kinetics (cfDNA Ratio, the ratio of post-chemotherapeutic cfDNA to baseline cfDNA) well distinguished responsive individuals (CR/PR) from the non-responsive (PD/SD). Additionally, cfDNA Ratio was found negatively correlated with PFS in lung adenocarcinoma (LUAD), but not lung squamous-cell carcinoma (LUSC) which may be due to a limited number of LUSC patients in this cohort. LUAD patients with low cfDNA Ratio have prolonged PFS and improved ORR, compared to those with high cfDNA Ratio. When stratified by therapy regimen, the predictive value of cfDNA Ratio is significant in patients with chemotherapy plus VEGFIs, while more patients need be included to validate the value of cfDNA Ratio in other regimens. Thus, the kinetics of plasma cfDNA during chemotherapy may function as a prognostic biomarker and efficacy predictor for NSCLC patients.

Download Full-text

Harmonization of Epidermal Growth Factor Measurements: Paving the Way of Finding A Biomarker in Non-Small Cell Lung Cancer

Biosciences Biotechnology Research Asia ◽

10.13005/bbra/2748 ◽

2016 ◽

Vol 16 (2) ◽

pp. 327-332

Author(s):

Idania González-Pérez ◽

Kalet León Monzón

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Diagnostic Value ◽

Small Cell ◽

Healthy Individuals ◽

Small Cell Lung ◽

Epidermal Growth ◽

Nsclc Patients

Literature reports only a few contradictory findings regarding the capacity of serum EGF concentrations to differentiate between healthy individuals and patients suffering non-small cell lung cancer (NSCLC). Therefore, the possible diagnostic capacity of serum EGF levels, suggestive of dependency on this growth factor in NSCLC patients/tumors and hence indicative of possible response to therapies directed to EGF/EGFR, is controversial. Inconsistencies likely derive from the lack of harmonization and even standardization in methodologies for blood and sera processing. This manuscript is a mini-review of a recently published study, where the control of the key factors that influence the concentration of EGF in serum, along with the normalization of EGF concentrations by platelets count, allowed to clarify the diagnostic value of serum EGF levels. Several EGF-related variables were identified as potential biomarkers in NSCLC, particularly those normalized by platelets, which highlighted the differences between patients and controls. Additionally, the study revealed that NSCLC patients differ from healthy individuals not by the total stock of EGF, but by its higher accessibility to serum. The increase in free/accessible EGF in blood circulation is probably relevant to the biology of NSCLC, most likely because it reflects a higher accessibility to this tumoral growth factor.

Download Full-text

Prognostic value of cripto-1 expression in non-small-cell lung cancer patients: a systematic review and meta-analysis

Biomarkers in Medicine ◽

10.2217/bmm-2019-0159 ◽

2020 ◽

Vol 14 (4) ◽

pp. 317-329

Author(s):

Yuanfeng Wei ◽

Jinfang Jiang ◽

Chengyan Wang ◽

Hong Zou ◽

Xihua Shen ◽

...

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Meta Analysis ◽

Clinical Stage ◽

Small Cell ◽

Small Cell Lung ◽

Poor Overall Survival ◽

Nsclc Patients

Aim: This systematic review and meta-analysis aimed to analyze the association between cripto-1 expression and prognosis as well as clinicopathological features of non-small-cell lung cancer (NSCLC) patients. Methods: The electronic databases for all articles about NSCLC and cripto-1 expression were searched. Results: Twelve articles were enrolled in this meta-analysis (3130 samples). In NSCLC patients, cripto-1 was expressed higher than in normal tissues. Cripto-1 expression was closely correlated with lymph node metastasis, histological differentiation and advanced clinical stage of NSCLC patients, but not related to smoking, age and gender. Pooled hazard ratios found that high cripto-1 expression had poor overall survival and progression-free survival. Conclusion: Cripto-1 could serve as a novel biomarker for predicting poor prognosis in NSCLC patients.

Download Full-text